EP0227494B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Pharmaceutical composition of the type which undergoes liquid-gel phase transition
Assignee: CHIBRET INTERNATIONAL
•
Filing: 1986-10-02
•
Granted: 1992-03-04
•
Expires: 2006-10-02
Abstract
Abstract The present invention relates to a pharmaceutical composition intended for contacting with a physiological liquid characterized in that said composition is intended to be administered as a non-gelled liquid form and is intended to gel in situ, this composition containing at least one polysaccharide in aqueous solution, of the type which undergoes liquid-gel phase transition gelling in situ under the effect of an increase in the ionic strength of said physiological liquid.
Inventors
- 👤 Claude Mazuel
- 👤 Marie-Claire Friteyre
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 22:42
CPC Classifications
A; A61; A61K; A61K9/00; C; C12; C12P; C12P19/00; C12P19/04; A61K47/00; A61K47/30; A61K47/36; A61K9/0012; A61K9/0048
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
66 words
Ophthalmological composition intended for contacting with the lacrimal fluid characterized in that said composition is intended to be administered as a non-gelled liquid form and is intended to gel in situ, this composition containing at least one polysaccharide in aqueous solution, of the type which undergoes liquid-gel phase transition gelling in situ under the effect of an increase in the ionic strength of said lacrimal fluid.
Claim 2
Dependent Claim
18 words
Composition as claimed in claim 1 , in which the polysaccharide is obtained by fermentation of a microorganism.
Claim 3
Dependent Claim
13 words
Composition as claimed in claim 2 in which the microorganism is Pseudomonas elodea.
Claim 4
Dependent Claim
33 words
Composition as claimed in claim 1 in which the polysaccharide has as its basic tetrasaccharide unit → 3)-β-D-Glcp-(1→ 4)-β-D-GlcpA-(1→ 4)-β-D-Glcp-(1→ 4)-α-L-Rhap-(1→ which may, or may not, be partially 0-acetylated on its β-D-glycopyranosyl residues.
Claim 5
Dependent Claim
22 words
Composition as claimed in one of claims 1 to 4, which contains 0.1 to 2.0 % by weight of the said polysaccharide.
Claim 6
Dependent Claim
18 words
Composition as claimed in one of claims 1 to 5 which contains in addition a tonicity adjusting agent.
Claim 7
Dependent Claim
20 words
Composition as claimed in claim 6, in which the tonicity adjusting agent is a sugar such as mannitol or sorbitol.
Claim 8
Dependent Claim
23 words
Composition as claimed in one of claims 1 to 7, which contains at least one pharmaceutically active substance for curative or diagnostic purposes.
Claim 9
Dependent Claim
18 words
Composition as claimed in claim 8, in which the pharmaceutically active substance is timolol or a derivative thereof.
Claim 10
Dependent Claim
37 words
Composition as claimed in claim 8 or 9 which contains 0.1 to 2.0 % by weight of polysaccharide and 0.001 to 5 % by weight of at least one pharmaceutically active substance for curative or diagnostic purposes.
Claim 11
Dependent Claim
19 words
Composition as claimed in one of claims 1 to 10 in which the pharmaceutically active substance is in solution.
Claim 12
Dependent Claim
19 words
Composition as claimed in one of claims 1 to 10 in which the pharmaceutically active substance is in suspension.
Claim 13
Dependent Claim
19 words
Composition as claimed in one of claims 1 to 10 in which the pharmaceutically active substance is in emulsion.
Claim 14
Dependent Claim
15 words
Composition for application to mucous membrane as claimed in one of claims 1 to 13.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.